Evaluation of antibody parameters as potential correlates of protection or enhancement by experimental vaccines to equine infectious anemia virus

Virology

Volumn 262, Issue 2, 1999, Pages 416-430

  Hammond, Scott A ^a   Raabe, Michelle L ^a   Issel, Charles J ^b   Montelaro, Ronald C ^a  

^a UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF KENTUCKY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ENVELOPE PROTEIN; IMMUNOGLOBULIN G; VIRUS VACCINE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY RESPONSE; ANTIBODY SPECIFICITY; ANTIBODY TITER; ANTIGEN BINDING; ARTICLE; EQUINE INFECTIOUS ANEMIA VIRUS; HORSE DISEASE; IN VITRO STUDY; NONHUMAN; PRIORITY JOURNAL; VACCINATION; VIRUS REPLICATION;

EID: 0033619219     PISSN: 00426822     EISSN: None     Source Type: Journal    
DOI: 10.1006/viro.1999.9939     Document Type: Article

References (39)

1. Ball J. M., Rao V. S. V., Robey W. G., Issel C. J., Montelaro R. C. Lentivirus antigen purification and characterization: Isolation of equine infectious anemia virus gag and env proteins in one step by reverse phase HPLC and application to human immunodeficiency virus glycoproteins. J. Virol. Methods. 19:1988;265-277.
2. Beatty J. A., Willett B. J., Gault E. A., Jarrett O. A longitudinal study of feline immunodeficiency virus-specific cytotoxic T lymphocytes in experimentally infected cats, using antigen-specific induction. J. Virol. 70:1996;6199-6206.
3. Berek, C.1999. Affinity maturation. InFundamental Immunology, 4th ed. (W. E. Paul, Ed.), pp. 863-878. Lippincott-Raven, Philadelphia.
4. + cytotoxic T-lymphocyte activity associated with control of viremia in primary human immunodeficiency virus type 1 infection. J. Virol. 68:1994;6103-6110.
5. Clements J. E., Montelaro R. C., Zink M. C., Amedee A. M., Miller S., Trichel A. M., Jagerski B., Hauer D., Martin L. N., Bohm R. P., Murphey-Corb M. Cross-protective immune responses induced in rhesus macaques by immunization with attenuated macrophage-tropic simian immunodeficiency virus. J. Exp. Med. 69:1995;2737-2744.
6. Cole K. S., Murphey-Corb M., Narayan O., Joag S. V., Shaw G. M., Montelaro R. C. Common themes of antibody maturation of simian immunodeficiency virus, simian-human immunodeficiency virus, and human immunodeficiency virus type 1 infections. J. Virol. 72:1998;7852-7859.
7. Cole K. S., Rowles J. L., Murphey-Corb M., Clements J. E., Unangst T., Robinson J., Desrosiers R. C., Wyand M. S., Montelaro R. C. Evolution of envelope-specific antibody responses in monkeys experimentally infected or immunized with SIV and its association with the development of protective immunity. J. Virol. 71:1997;5069-5079.
8. Connor R. I., Montefiori D. C., Binley J. M., Moore J. P., Bonhoeffer S., Gettie A., Fenamore E. A., Sheridan K. E., Ho D. D., Dailey P. J., Marx P. A. Temporal analyses of virus replication, immune responses, and efficacy in rhesus macaques immunized with a live, attenuated simian immunodeficiency virus vaccine. J. Virol. 72:1998;7501-7509.
9. Cook R. F., Leroux C., Cook S. J., Berger S. L., Lichtenstein D. L., Ghabrial N. N., Montelaro R. C., Issel C. J. Development and characterization of an in vivo pathogenic molecular clone of equine infectious anemia virus. J. Virol. 72:1998;1383-1393.
10. Flynn J. N., Keating P., Hosie M. J., Mackett M., Stephens E. B., Beatty J. A., Neil J. C., Jarret O. Env-specific CTL predominate in cats protected from feline immunodeficiency virus infection by vaccination. J. Immunol. 157:1996;3658-3665.
11. Grund C., Lechman E., Pezzuolo N., Issel C., Montelaro R. Fine specificity of equine infectious anaemia virus gp90-specific antibodies associated with protective and enhancing immune responses in experimentally infected and immunized ponies. J. Gen. Virol. 77:1996;435-442.
12. Hammond S. A., Cook S. J., Lichtenstein D. L., Issel C. J., Montelaro R. C. Maturation of the cellular and humoral immune responses to persistent infection in horses by equine infectious anemia virus is a complex and lengthy process. J. Virol. 71:1997;3840-3852.
13. Hosie M. J., Flynn J. N. Feline immunodeficiency virus vaccination: Characterization of the immune corelates of protection. J. Virol. 70:1996;7561-7568.
14. Issel C. J., Horohov D. W., Lea D. F., Adams W. V. Jr., Hagius S. D., McManus J. M., Allison A. C., Montelaro R. C. Efficacy of inactivated whole-virus and subunit vaccines in preventing infection and disease caused by equine infectious anemia virus. J. Virol. 66:1992;3398-3408.
15. Joag S. V., Liu Z. Q., Stephens E. B., Smith M. S., Kumar A., Li Z., Wang C., Sheffer D., Jia F., Foresman L., Adany I., Lifson J., McClure H. M., Narayan O. Oral immunization of macaques with attenuated vaccine virus induces protection against vaginally transmitted AIDS. J. Virol. 72:1998;9069-9078.
16. Johnson R. P., Glickman R. L., Yang J. Q., Kaur A., Dion J. T., Mulligan M. J., Desrosiers R. C. Induction of vigorous cytotoxic T-lymphocyte responses by live attenuated simian immunodeficiency virus. J. Virol. 71:1997;7711-7718.
17. Johnson R. P., Lifson J. D., Czajak S. C., Cole K. S., Manson K. H., Glickman R., Yang J., Montefiori D. C., Montelaro R., Wyand M. S., Desrosiers R. C. Highly attenuated vaccine strains of simian immunodeficiency virus protect against vaginal challenge: Inverse relationship of degree of protection with level of attenuation. J. Virol. 73:1999;4952-4961.
18. Koup R. A., Safrit J. A., Cao Y., Andrews C. A., McLeod G., Borkowsky W., Farthing C., Ho D. D. Temporal association of cellular immune responses with the initial control of viremia in primary human immunodeficiency virus type 1 syndrome. J. Virol. 68:1994;4650-4655.
19. Li, F, Leroux, C, Craigo, J, Cook, S. J, Issel, C. J, and, Montelaro, R. C. The S2 gene of equine infectious anemia virus is a highly conserved determinant of viral replication properties in experimentally infected ponies. (manuscript submitted).
20. Li F., Puffer B. A., Montelaro R. C. The S2 gene of equine infectious anemia virus is dispensable for viral replication in vitro. J. Virol. 72:1998;8344-8348.
21. Lichtenstein D. L., Rushlow K. E., Cook R. F., Raabe M. L., Swardson C. J., Kociba G. J., Issel C. J., Montelaro R. C. Replication in vitro and in vivo of an equine infectious anemia virus mutant deficient in dUTPase activity. J. Virol. 69:1995;2881-2888.
22. Malmquist W. A., Barnett D., Becvar C. S. Production of equine infectious anemia antigen in a persistently infected cell line. Arch. Virol. 42:1973;361-370.
23. Matteucci D., Pistello M., Mazzetti P., Giannecchini S., Del Mauro D., Lonetti I., Zaccaro L., Pollera C., Specter S., Bendinelli M. Studies of AIDS vaccination using an ex vivo feline immunodeficiency virus model: Protection conferred by a fixed-cell vaccine against cell-free and cell-associated challenge differs in duration and is not easily boosted. J. Virol. 71:1997;8368-8376.
24. Mazzetti P., Giannecchini S., Del Mauro D., Matteucci D., Portincasa P., Merico A., Chezzi C., Bendinelli M. AIDS vaccination studies using an ex vivo feline immunodeficiency virus model: Detailed analysis of the humoral immune response to a protective vaccine. J. Virol. 73:1999;1-10.
25. + cytotoxic T lymphocytes from horses with equine infectious anemia virus recognize env and gag/pr proteins. J. Virol. 68:1994;1459-1467.
26. Montelaro R. C., Cole K. S., Hammond S. A. Maturation of immune responses to lentivirus infection: Implications for AIDS vaccine development. AIDS Res. Human Retrovir. 14:1998;S225-S229.
27. Montelaro R. C., West M., Issel C. J. Isolation of equine infectious anemia virus glycoproteins: Lectin affinity chromatography procedures for high avidity glycoproteins. J. Virol. Methods. 6:1983;337-346.
28. Polacino P., Stallard V., Klaniecki J. E., Montefiori D. C., Langlois A. J., Richardson B. A., Overbaugh J., Morton W. R., Benveniste R. E., Hu S.-L. Limited breadth of the protective immunity elicited by simian immunodeficiency virus SIVmne gp160 vaccines in a combination immunization regimen. J. Virol. 73:1999;618-630.
29. Raabe M., Issel C., Cook S., Cook R., Woodson B., Montelaro R. Immunization with a recombinant envelope protein (rgp90) of EIAV produces a spectrum of vaccine efficacy ranging from lack of clinical disease to severe enhancement. Virology. 245:1998;151-162.
30. Raabe M. L., Issel C. J., Montelaro R. C. In vitro antibody-dependent enhancement assays are insensitive indicators of in vivo vaccine enhancement of equine infectious anemia virus. Virology. 259:1999;416-427.
31. Richmond J. F. L., Lu S., Santoro J. C., Weng J., Hu S.-L., Montefiori D. C., Robinson H. L. Studies of the neutralizing activity and avidity of anti-human immunodeficiency virus type 1 env antibody elicited by DNA priming and protein boosting. J. Virol. 72:1998;9092-9100.
32. Rwambo P. M., Issel C. J., Hussain K. A., Montelaro R. C. In vitro isolation of a neutralization escape mutant of equine infectious anemia virus (EIAV). Arch. Virol. 111:1990;275-280.
33. Sellon D. C., Fuller F. J., McGuire T. C. The immunopathogenesis of equine infectious anemia virus (Review). Virus Res. 32:1994;111-138.
34. Snapper, C. M., and Finkelman, F. D.1999. Immunoglobulin class switching. InFundamental Immunology, 4th ed. (W. E. Paul, Ed.), pp. 831-861. Lippincott-Raven, Philadelphia.
35. Stephens E. B., Joag S. V., Atkinson B., Sahni M., Li Z., Foresman L., Adany I., Narayan O. Infected macaques that controlled replication of SIVmac or nonpathogenic SHIV developed sterilizing resistance against pathogenic SHIV (KU-1). Virology. 234:1997;328-339.
36. Sugiura T., Kondo T., Imagawa H., Kamada M. Production of monoclonal antibodies to six isotypes of horse immunoglobulin. Vet. Immunol. Immunopathol. 62:1998;145-151.
37. Van Rompay K. K. A., Berardi C. J., Dillard-telm S., Tarara R. P., Canfield D. R., Valverde C. R., Montefiori D. C., Cole K. S., Montelaro R. C., Miller C. J., Marthas M. L. Passive immunization of newborn rhesus macaques prevents oral simian immunodeficiency virus infection. J. Infect. Dis. 177:1998;1247-1259.
38. Wang S., Rushlow K., Issel C., Cook R., Cook S., Raabe M., Chong Y.-H., Costa L., Montelaro R. C. Enhancement of EIAV replication and disease by immunization with a baculovirus-expressed recombinant envelope surface glycoprotein. Virology. 199:1994;247-251.
39. Wyand M. S., Manson K. H., Garcia-Moll M., Montefiori D., Desrosiers R. C. Vaccine protection by a triple deletion mutant of simian immunodeficiency virus. J. Virol. 70:1996;3724-3733.